BED BATH & BEYOND, INC. (BBBY): what the price requires
The current priced-in claim for BED BATH & BEYOND, INC. (BBBY) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.
Generated: 2026-07-19 · Source: https://boothcheck.com/report/BBBY
Headline
| Field | Value |
|---|---|
| Ticker | BBBY |
| Company | BED BATH & BEYOND, INC. |
| Current price | $5.03/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | revenue-multiple |
| EV / sales paid | 0.2x |
| Steady-state operating margin assumed | 9.9% |
The price sits below what even a 5%/yr revenue decline would warrant; the inversion reports a bound, not a solved growth path.
The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.
Solve inputs: computed at a 12.8% cost of capital with 4% terminal growth over a 5-year stage, holding a 9.9% terminal operating margin (24.7% gross margin x the 40% mature-conversion prior).
How unusual the bet is: within-range (limited comparison data)
| Reference | Value |
|---|---|
| vs own history | +0.12σ |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple; asset-based/growth-DCF land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 1.81x | 2 | expensive |
| Earnings | — | 0 | — |
| Relative | 0.22x | 2 | justifies |
| Growth | 2.54x | 2 | expensive |
Families that justify the price: Relative Families that call it expensive: Asset, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.
Per-Model Detail (n=6)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $0.00 | — | no | Negative/zero FCF — equity value floored at $0 |
| DCF Exit Multiple | Growth | $0.00 | — | no | Negative/zero FCF or EBITDA — equity value floored at $0 |
| Relative Valuation | Relative | $23.04 | 0.22x | yes | P/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $2.93 | 1.72x | yes | Book value floor: BV/sh $2.93, ROE negative |
| Two-Stage Excess Return | Asset | $2.63 | 1.91x | yes | Book value with convergence: BV/sh $2.93, ROE converges to ke |
| Discounted Future Market Cap | Growth | $1.11 | 4.53x | yes | Rev $1.1B, growth -12% (input: historical growth; tapered), Terminal P/S: 0.2x / 0.3x / 0.4x (bear / base = today's held flat / bull, cap 15x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | $9.01 | 0.56x | yes | Margin ramp: -6% → 12% over 7yr, rev growth 0% (input: historical growth; tapered) |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $23.04 | 0.22x | yes | Revenue $1.06B × sector P/S 1.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $120.3m |
| Share count CAGR (dilution) | 12.4% |
| Burning cash | yes |
Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.
Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.
Bullet Takeaways
- This is not the old retailer; it is the company formerly known as Beyond (and Overstock) that took the Bed Bath & Beyond name and BBBY ticker in 2025, now running an asset-light online portfolio of Bed Bath & Beyond, Overstock, buybuy BABY, and Kirkland's Home brands.
- The biggest structural risk is shrinking with a cash burn: full-year 2025 revenue fell 25% to about $1.0 billion and the company is still losing money, so the turnaround depends on stabilizing the top line before the cash runs thin.
- What moves the stock next is whether the loss-narrowing continues into revenue growth: net loss improved to $85 million from $259 million and management targets low-to-mid single-digit growth in 2026.
Bull Case
The obvious objection comes first: this looks like a dying retailer. Revenue fell 25% in 2025 to roughly $1.0 billion, the company is still unprofitable, and it carries one of the most famous bankruptcy names in recent retail history. A reader could dismiss it on sight. But the dismissal misreads what the company actually is now, and the data pushes back on the death-spiral story. The losses are shrinking fast: full-year net loss narrowed to $85 million from $259 million the prior year, and the adjusted EBITDA loss improved to $31 million from $144 million. That is the eighth consecutive quarter of measurable progress toward profitability, and gross margin expanded 390 basis points to 24.7%. A business losing less money every quarter while widening its margin is not in a death spiral; it is restructuring.
The reason the model can work is that it is asset-light. This is the former Overstock e-commerce platform wearing well-known retail brand names, not a chain of leased stores. The filing describes the structure plainly: "Our asset-light supply chain allows us to ship directly to customers from our partners or our warehouses, which primarily handle orders from our partners' owned inventory." In an asset-light marketplace, the company does not own most of the inventory or carry the fixed cost of physical stores, so it can scale revenue without the capital intensity that sank the original Bed Bath & Beyond. The filing also notes the company can "launch new websites at a relatively low cost", which is how it bolts on brands like Kirkland's Home and buybuy BABY cheaply.
The price reflects almost none of this. At roughly 0.2 times revenue, the market values the company below what even a continued 5% annual revenue decline would warrant. The company carries net cash of about $120 million and no meaningful debt, and it also holds a blockchain asset portfolio including tZERO, an extra source of value the retail-failure narrative ignores. Management targets a return to low-to-mid single-digit revenue growth in 2026. The bull case is that an asset-light, net-cash marketplace with recognizable brands, a sharply narrowing loss, and a fraction-of-revenue price has real option value if the top line stabilizes, and the market is pricing it as if it will not.
Bear Case
The balance-sheet truth is that this company is shrinking and burning cash at the same time, and that combination has a clock on it. Revenue fell 25% in 2025 to about $1.0 billion, continuing a multi-year decline, and the business still posted an operating loss and consumed cash. Net cash of roughly $120 million is the cushion, but a company that loses money while its revenue contracts is spending down that cushion, and the share count has grown more than 12% over the past year as it issues stock. Dilution is the bear's quiet mechanism here: even if the turnaround works, today's holder owns a steadily smaller piece of it, and if the cash gets thin the company will have to raise more equity at whatever price the market offers.
The competitive position is brutal and the filing does not hide it. The company competes, in its own words, against "online retailers with or without discount departments, including Amazon.com, AliExpress (part of the Alibaba Gro"up. Competing in general-merchandise e-commerce against Amazon is the hardest game in retail: Amazon has lower prices, faster delivery, and a logistics network no one can match. An asset-light marketplace selling home goods and general merchandise has no structural moat against that, and the 25% revenue decline is the market voting on whether the brand names alone are enough to hold customers. They have not been so far.
The valuation is cheap for a reason, and the inversion shows it. Because the company loses money, the price is read against sales, and even at 0.2 times revenue the bet is not trivial: the price assumes the business eventually earns close to a 10% operating margin, which it is nowhere near, and stops shrinking. The value methods that anchor on the current reality, the revenue-multiple and book-value lenses, land below the price once you account for the losses, and the methods that reach the price require a margin ramp from negative to double-digit that the company has only just begun to show. The blockchain assets add optionality but also volatility and distraction from the core retail fix. The bear case is structural: a shrinking, loss-making, diluting general-merchandise marketplace facing Amazon is a turnaround that has to outrun its own cash burn, and the cheap multiple is the market pricing the real possibility that it does not.
Valuation
The company loses money, so the price is read against its sales rather than its earnings, and on that basis it is strikingly cheap: about 0.2 times revenue, below what even a continued 5% annual revenue decline would warrant. The catch in the inversion is the margin assumption underneath that cheap multiple. Reaching the price still requires the business to earn close to a 10% operating margin eventually, drawn from a 24.7% gross margin and a normal retail conversion of gross to operating profit. The company is far from that margin today; it is still operating at a loss. So the low revenue multiple is not a free lunch, it is the market pricing both a deep margin gap and a shrinking top line.
The methods split along the turnaround fault line. The revenue-multiple read and the book-value floor land below the current price once the losses are accounted for, because the company's reported economics do not yet support the price. The margin-trajectory method, which assumes the operating margin ramps from negative toward double digits over several years, reaches closer to the price, but it is explicitly an assumption about a recovery, not a measurement of one. In plain terms, the price is supported only if you believe the margin ramp and revenue stabilization the company has begun to show actually complete. The static methods, anchored on the current loss-making reality, value it lower.
Solvency is the boundary that matters most for a cash-burning business. The company holds roughly $120 million of net cash with no meaningful debt and about $136 million of liquid assets, plus a blockchain asset portfolio that adds value outside the operating business. That cushion buys time, but the share count growing more than 12% in a year shows the company is funding itself partly with equity, which dilutes holders. The most decisive point for the valuation is the race between the narrowing loss and the shrinking revenue: at 0.2 times sales the buyer is paying almost nothing for the brands and the marketplace, but the bet only pays off if the top line stabilizes and the margin ramp continues before the cash and the patience run out.
Catalysts
The defining context is the corporate transformation: Beyond, Inc., the former Overstock, changed its name to Bed Bath & Beyond, Inc. and reclaimed the BBBY ticker on the New York Stock Exchange in August 2025, and now operates a portfolio of Bed Bath & Beyond, Overstock, buybuy BABY, and Kirkland's Home brands plus a blockchain asset portfolio. This is a different company from the retailer that went bankrupt in 2023, and the brand names are licensed assets on an asset-light e-commerce platform.
The trajectory is the catalyst the bull case watches. For full-year 2025 the company reported net revenue of about $1.0 billion, down 25%, but the net loss narrowed sharply to $85 million from $259 million and the adjusted EBITDA loss improved to $31 million from $144 million, the eighth straight quarter of measurable improvement toward profitability. The fourth quarter showed revenue stabilizing somewhat, down 9.8% to $273 million with the net loss narrowing to $21 million and a $118 million year-over-year improvement in operating cash flow use.
The forward catalysts are revenue stabilization and the Kirkland's integration. Management targets a return to low-to-mid single-digit revenue growth in 2026, which would mark the inflection from shrinking to growing, and the Kirkland's Home merger adds a brand but also transaction and transition costs that may weigh on near-term results. The next quarterly reports, with the revenue growth rate against the 2026 target and the continued progress on the loss, are the cleanest read on whether the turnaround crosses from narrowing losses into actual growth.
Peer Cohorts (Per Segment, With Filing Citations)
Retail (reported)
- W (WAYFAIR INC.)
- (no filing in the citation store)
- WSM (WILLIAMS-SONOMA, INC.)
- (no filing in the citation store)
- RH (RH)
- (no filing in the citation store)
- CHWY (CHEWY, INC.)
- (no filing in the citation store)
- RVLV (REVOLVE GROUP, INC.)
- (no filing in the citation store)
- GCT (GIGACLOUD TECHNOLOGY INC)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
company rebrand disclosure, August 2025 · Bed Bath & Beyond FY2025 results · company disclosures · Bed Bath & Beyond Q4 2025 results · Bed Bath & Beyond FY2025 results and outlook